Source: International Congress 2017 – Translational studies of lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Souza (Santos/Sp, Brazil). Specific NFKappaB and Rho-Quinase inhibitors compared to corticosteroid in asthma model in mice. 3923

Member's Comments

No comment yet.

Related content which might interest you: The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodelling in an asthma model in mice Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 MIF antagonism restores corticosteroid sensitivity in a murine model of severe asthma Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Dissociation of the effects of a steroid on inflammation compared to airway hyperresponsiveness (AHR) in a model of asthma in conscious mice Source: Eur Respir J 2001; 18: Suppl. 33, 30s Year: 2001 Improving of experimental allergic asthma by decreased Th2 responses in OGR-1 knockout mice Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012 Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Overexpression of eNOS suppresses asthmatic features in a mouse model of allergic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002 Models of asthma employing ovalbumin in rats and mice: similarities and differences compared with patient asthma Source: Annual Congress 2005 - PG11 - Experimental models for COPD and asthma Year: 2005 Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Plant protease inhibitors compared to corticosteroids in mice with Asthma-COPD Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Roflumilast inhibits chemokine release in animal models of COPD and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004 Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 The deletion of Bambi attenuates experimental asthma in mice Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019